ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,408.42
      -1.73%
      US Tech 100
      17,870.94
      -3.09%
      Dow Jones
      40,345.41
      -1.01%
      Brent Oil
      71.545
      0.92%
      Bitcoin
      54,820.10
      1.19%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NYSE

      6. Takeda Pharmaceutical Company Ltd (TAK) Quote

      Takeda Pharmaceutical Company Ltd

      Takeda Pharmaceutical Company Ltd (TAK)

      Taku Gold Corp
      14.81
      -0.11
      (-0.74%)
      Closed September 08 4:00PM
      Delayed by 15 minutes
      14.81
      0.00
      (0.00%)
      After Hours: 6:30PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      14.81
      Bid
      -
      Ask
      -
      Volume
      1,480,340
      14.79 Day's Range 14.915
      12.575 52 Week Range 16.39
      Market Cap
      46.474B
      Previous Close
      14.92
      Open
      14.89
      Last Trade
      67879
      @
      14.81
      Last Trade Time
      Financial Volume
      $ 21,961,523
      VWAP
      14.8355
      Average Volume (3m)
      2,250,166
      Shares Outstanding
      3,138,026,928
      Dividend Yield
      4.13%
      PE Ratio
      1.07
      Earnings Per Share (EPS)
      45.91
      Revenue
      4.28T
      Net Profit
      144.07B

      About Takeda Pharmaceutical Company Ltd

      Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geogr... Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Diversified
      Website
      www.takeda.co.jp
      Headquarters
      Chuo, Tokyo, Jpn
      Founded
      1984
      Takeda Pharmaceutical Company Ltd is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker TAK. The last closing price for Takeda Pharmaceutical was $14.92. Over the last year, Takeda Pharmaceutical shares have traded in a share price range of $ 12.575 to $ 16.39.

      Takeda Pharmaceutical currently has 3,138,026,928 shares outstanding. The market capitalization of Takeda Pharmaceutical is $46.82 billion. Takeda Pharmaceutical has a price to earnings ratio (PE ratio) of 1.07.

      Ask ADVFN Intelligence (AI)

      TAK Latest News

      More News

      Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

      − cTTP is an Ultra-rare, Potentially Fatal Blood-Clotting Disorder with Limited Treatment Options; Untreated, Acute TTP Events Have a Mortality Rate of >90%1,2 − Approval Based on Totality of...

      August 07 2024
      Business Wire

      Takeda annonce ses résultats financiers pour le premier trimestre de son exercice 2024 – Excellente performance au niveau des produits de croissance et de lancement ; des progrès dans le pipeline prometteur à un stade avancé

      Croissance du chiffre d’affaires de 14,1 % à taux de change réels (TCR) et de 2,1 % à taux de change constants (TCC), portée par une accélération des produits de croissance et de lancement...

      July 31 2024
      Business Wire

      Takeda gibt Ergebnisse für das erste Quartal des Geschäftsjahres 2024 bekannt - Starke Leistung von Wachstums- und Einführungsprodukten; Fortschritte in der vielversprechenden Pipeline im Spätstadium

      Umsatzwachstum von 14,1 % zu aktuellen Wechselkursen (AER); +2,1 % zu konstanten Wechselkursen (CER), angetrieben durch die Beschleunigung der Wachstums- und Einführungsprodukte (+17,8 % zu CER...

      July 31 2024
      Business Wire

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

      July 31 2024
      Edgar (US Regulatory)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

      July 31 2024
      Edgar (US Regulatory)

      AMD Shares Surge 9% on Earnings Beat; Match Group Rises 10%, Pinterest & Lemonade Drop 13%, and More Earnings Updates

      Advanced Micro Devices (NASDAQ:AMD) – The semiconductor and processor company reported adjusted second-quarter earnings of 69 cents per share and $5.84 billion in revenue, beating the 68...

      July 31 2024
      IH Market News

      武田薬品工業: 2024年度第1四半期業績を公表 - 成長製品・新製品は力強い勢いを示し、後期開発段階の有望なパイプラインが進展

      売上収益は、実勢レート（AER：Actual Exchange Rate）ベースで対前年同期+14.1%、恒常為替レート（CER：Constant Exchange Rate）ベースで同+2.1%成長し、成長製品・新製品が牽引（CERベースで同+17.8%） Core...

      July 31 2024
      Business Wire

      Form 144 - Report of proposed sale of securities

      July 10 2024
      Edgar (US Regulatory)

      Form 144 - Report of proposed sale of securities

      July 10 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.02-0.13486176668914.831514.79163929114.92039123DR
      41.047.5526506899113.7715.0813.76171634814.70775784DR
      121.7413.312930374913.0715.0812.575225016613.78502535DR
      260.21.3689253935714.6115.0812.575187682713.69995039DR
      52-0.45-2.9488859764115.2616.3912.575188319714.10361082DR
      156-2.14-12.625368731616.9517.3112.28235029514.56970397DR
      260-2.53-14.590542099217.3420.9512.28212808415.62350299DR

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      AGXArgan Inc
      $ 89.89
      (25.93%)
      		1.33M
      NXQuanex Corp
      $ 30.32
      (21.96%)
      		2.42M
      EAFGrafTech International Ltd
      $ 0.6898
      (14.62%)
      		1.68M
      GTN.AGray Television Inc
      $ 8.00
      (13.64%)
      		5.76k
      IOTSamsara Inc
      $ 43.99
      (13.52%)
      		12.52M
      PLPlanet Labs PBC
      $ 1.77
      (-28.63%)
      		11.4M
      SOSSOS Limited
      $ 0.5306
      (-16.12%)
      		436.44k
      AMPXAmprius Technologies Inc
      $ 0.7141
      (-12.97%)
      		1.04M
      AMNAMN Healthcare Services Inc
      $ 45.64
      (-12.58%)
      		1.04M
      GCOGenesco Inc
      $ 26.00
      (-11.86%)
      		497.58k
      NIONIO Inc
      $ 5.03
      (3.71%)
      		105.41M
      TAT&T Inc
      $ 20.97
      (1.55%)
      		53.08M
      PLTRPalantir Technologies Inc
      $ 30.33
      (0.56%)
      		50.95M
      NUNu Holdings Ltd
      $ 13.71
      (-4.39%)
      		48.84M
      FFord Motor Company
      $ 10.59
      (-1.67%)
      		47.67M

      TAK Discussion

      View Posts
      Monksdream Monksdream 5 months ago
      TAK over $10
      👍️0
      Boing x 2 Boing x 2 2 years ago
      Just saying,

      https://www.takeda.com/newsroom/newsreleases/2022/takedas-biologics-license-application-bla-for-dengue-vaccine-candidate-tak-003-granted-priority-review-by-us-food-and-drug-administration

      4 months or less until an answer. Expedited review is six months or less now. It was accepted Nov 22nd.

      Big if we get FDA apprvoval. ETF's in the know are sucking up shares.

      Other approved drug has serious side effects vs. ours.

      300M cases a year from mosquito bites.

      Boing X 2
      👍️0
      Phosphene Phosphene 4 years ago
      Takeda’s Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next Decade

      https://www.businesswire.com/news/home/20201208005955/en/Takeda%E2%80%99s-Pipeline-Has-Potential-to-Contribute-Significantly-to-Revenue-Growth-Over-Next-Decade
      👍️0
      Phosphene Phosphene 4 years ago
      Japan's Takeda eyes new focus on vaccines after OTC asset sales - CEO

      https://www.reuters.com/article/health-coronavirus-takeda-vaccines-idUSKBN27M0F7
      👍️0
      Phosphene Phosphene 4 years ago
      MIT-Takeda program launches

      Research projects will harness the power of artificial intelligence to positively impact human health.

      https://news.mit.edu/2020/mit-takeda-program-launches-research-ai-and-human-health-0618
      👍️0
      rising rising 6 years ago
      Takeda shares tumbled as much as 9.3 percent in early trading in Tokyo on Wednesday. The Japanese company is offering the equivalent of 49 pounds ($68.55) per share, including 27.26 pounds in stock and 21.75 pounds in cash, Shire said in a statement. That’s a 60 percent premium to Shire’s closing share price on March 27, before Takeda disclosed it was interested in the US drug maker.

      ADR is 3:1 - NICE!
      60 percent upside
      Added 36.83 US stock
      Added 29.38 US cash


      Not a bad deal!
      👍️0
      rising rising 6 years ago
      So how does the Shire shareholder make out on this deal?

      Takeda shares tumbled as much as 9.3 percent in early trading in Tokyo on Wednesday. The Japanese company is offering the equivalent of 49 pounds ($68.55) per share, including 27.26 pounds in stock and 21.75 pounds in cash, Shire said in a statement. That’s a 60 percent premium to Shire’s closing share price on March 27, before Takeda disclosed it was interested in the US drug maker.

      Where is the 60percent premium to Close of March 27 2018 at shire 128.87
      👍️0
      trendmkr trendmkr 9 years ago
      Takeda article: enGene Shines with a Host of Big Name Collaborations

      http://marketexclusive.com/engene-shines-with-a-host-of-big-name-collaborations/1281/
      👍️0

      Your Recent History

      NYSE
      TAK
      Takeda Pharmaceutical
      Delayed Upgrade Clock